Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CBLL
SELLCeriBell, Inc. · Healthcare · United States · $642M · Avg Vol: $7M/d
COMPANY DESCRIPTION
CeriBell, Inc. is a medical device company focused on developing non-invasive, rapid neurological assessment tools for the early detection and monitoring of acute neurological conditions such as stroke and concussion. The company's competitive moat lies in its proprietary technology for measuring brain electrical activity, offering the potential for significant clinical impact by enabling timely diagnosis and intervention in critical care and emergency settings. CeriBell represents a high-growth potential player targeting an unmet need in neurological diagnostics.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.9M | 45.2M | 65.4M | 89.1M | 50.9% | 95.1M | 114.0M | 145.9M | 28.0% |
| EPS | -1.59 | -1.26 | -3.39 | -1.46 | — | -1.59 | -1.68 | -1.10 | — |
| Shares | 34.0M | 34.0M | 35.9M | 37.5M | +10.2% | 37.9M | — | — | — |
| Debt | 18.2M | 14.2M | 22.0M | 22.3M | 6.9% | 22.1M | — | — | — |
| Equity | -86.4M | -112.3M | 191.2M | 155.3M | -18.7% | — | — | — | — |
| Op CF | -32.0M | -29.2M | -35.0M | -40.8M | — | -48.7M | — | — | — |
| Inv CF | -1.4M | -1.8M | -1.6M | -118.1M | — | — | — | — | — |
| Fin CF | 49.8M | -2.8M | 196.5M | 5.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CBLL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CBLL | CeriBell, Inc.(you) | $642M | 24 | SELL |
| BBNX | Beta Bionics, Inc. | $706M | 22 | SELL |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.1B | 26 | SELL |
| TNDM | Tandem Diabetes Care, Inc. | $1.2B | 25 | SELL |
| NPCE | NeuroPace, Inc. | $505M | 34 | SELL |
| AORT | Artivion, Inc. | $1.2B | 22 | SELL |
| IMR.AX | Imricor Medical Systems, Inc. | $455M | 15 | STRONG SELL |
| ATEC | Alphatec Holdings, Inc. | $1.3B | 27 | SELL |
| LAB | Standard BioTools Inc. | $326M | 22 | SELL |
| CTKB | Cytek Biosciences, Inc. | $576M | 41 | HOLD |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%